International Journal of Cancer最新文献

{"title":"Comparison of iBreastExam with clinical breast examination for early detection of breast cancer in community outreach clinics in Pune, India.","authors":"Smita N Joshi, Trupti S Dharpawar, Shekhar R Kulkarni, Pritam S Chaudhari, Ojus S Wadhwa, B Kishore Kumar, Rengaswamy Sankaranarayanan","doi":"10.1002/ijc.70137","DOIUrl":"https://doi.org/10.1002/ijc.70137","url":null,"abstract":"<p><p>Clinical breast examination (CBE) is the only feasible option for the low- and middle-income countries that have the rising burden of breast cancers but lack adequate infrastructure and human resources for organised mammography screening programmes. However, CBE is a subjective test and this warrants evaluation of alternatives to CBE. We conducted a cross-sectional study to evaluate the agreement between iBreastExam (iBE) and CBE for early detection of breast cancers. Women aged 40 to 69 years were screened at community outreach clinics after obtaining a written informed consent. Women were screened with CBE first followed by iBE by two independent trained healthcare providers. Those who were positive on either were referred to an expert breast surgeon masked to the screening test results. If the expert breast surgeon detected a lump, mammography and/or USG and biopsy were advised. Of the 10,004 women consented, CBE and iBE both were performed on 9994 women. Screen positivity by either test was 1.5% (151/9994). CBE and iBE both were positive in 97/9994 (0.97%) women. The crude agreement between CBE and iBE was 99.5% (K = 0.78, SE 0.029, 95% CI 0.72-0.84). Among the 9994 women screened, 14 (0.14%) breast cancers were detected. Three breast cancers were diagnosed among asymptomatic women who tested positive by CBE but negative by iBE. Refinement of iBE to improve its sensitivity and additional research studies are needed before deploying this device for breast cancer screening in any program.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145005677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating distant recurrence-free survival and location of metastasis in HER2+ breast cancer by ER status.","authors":"Damien Kaukonen, Alexander Ploner, Erwei Zeng, Jenny Bergqvist, Kamila Czene","doi":"10.1002/ijc.70135","DOIUrl":"https://doi.org/10.1002/ijc.70135","url":null,"abstract":"<p><p>Prognostic factors, such as the Human Epidermal growth factor Receptor 2 (HER2) and Estrogen Receptor (ER) influence distant recurrence-free survival (RFS) in breast cancer. This study aims to evaluate the interaction between HER2 and ER status with RFS, and if that interaction influences where the metastasis is located. To do this, we used a study population of all women diagnosed with non-metastatic, invasive breast cancer in Stockholm from 2007 to 2020. Flexible parametric survival models were used to estimate time-varying survival and hazard ratios (HR) for RFS. Cumulative incidence was used to quantify rates of metastasis in key locations. We found significant interactions between ER and HER2 for RFS (p = 0.037), which was time varying (p = 0.017). For ER+ patients, adjusted short-term survival at 2.5 years after diagnosis was identical for HER2+ compared to HER2- patients (HR 1.02, CI; 0.76-1.39), but was dramatically better for HER2+ patients after 5 years (HR at 7.5 years 0.29, CI; 0.14-0.58). In contrast, among ER- patients, HER2+ patients experienced constant risk compared to HER2- from diagnosis until the end of the study (HR ~0.50). Finally, we observed that HER2+ patients have a higher rate of first metastasis to the brain than HER2- patients (p < 0.001). Our study demonstrates that the interaction between ER and HER2 status has a time-varying impact on RFS and plays a role in determining the location of metastasis. Thus, the utilization of complex models that combine ER and HER2 status can enhance the understanding of patient RFS and the likelihood of metastasis in specific locations.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145005671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetically determined body mass index is associated with diffuse large B-cell lymphoma in polygenic and Mendelian randomization analyses.","authors":"Amy Moore, Eleanor Kane, Lauren R Teras, Mitchell J Machiela, Joshua Arias, Orestis A Panagiotou, Alain Monnereau, Nicole Wong Doo, Zhaoming Wang, Susan L Slager, Roel C H Vermeulen, Claire M Vajdic, Karin E Smedby, John J Spinelli, Joseph Vijai, Graham G Giles, Brian K Link, Alan A Arslan, Alexandra Nieters, Paige M Bracci, Nicola J Camp, Gilles Salles, Wendy Cozen, Henrik Hjalgrim, Immaculata De Vivo, Hans-Olov Adami, Demetrius Albanes, Nikolaus Becker, Yolanda Benavente, Simonetta Bisanzi, Paolo Boffetta, Paul Brennan, Angela R Brooks-Wilson, Federico Canzian, Jacqueline Clavel, Lucia Conde, David G Cox, Karen Curtin, Lenka Foretova, Hervé Ghesquières, Bengt Glimelius, Thomas M Habermann, Jonathan N Hofmann, Qing Lan, Mark Liebow, Anne Lincoln, Marc Maynadie, James McKay, Mads Melbye, Lucia Miligi, Roger L Milne, Thierry J Molina, Lindsay M Morton, Kari E North, Kenneth Offit, Marina Padoan, Sara Piro, Alpa V Patel, Mark P Purdue, Vignesh Ravichandran, Elio Riboli, Richard K Severson, Melissa C Southey, Anthony Staines, Lesley F Tinker, Ruth C Travis, Sophia S Wang, Elisabete Weiderpass, Stephanie Weinstein, Tongzhang Zheng, Stephen J Chanock, Nathaniel Rothman, Brenda M Birmann, James R Cerhan, Sonja I Berndt","doi":"10.1002/ijc.70039","DOIUrl":"https://doi.org/10.1002/ijc.70039","url":null,"abstract":"<p><p>Obesity has been associated with non-Hodgkin lymphoma (NHL), but the evidence is inconclusive. We examined the association between genetically determined adiposity and four common NHL subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, chronic lymphocytic leukemia, and marginal zone lymphoma, using eight genome-wide association studies of European ancestry (N = 10,629 cases, 9505 controls) and constructing polygenic scores for body mass index (BMI), waist-to-hip ratio (WHR), and waist-to-hip ratio adjusted for BMI (WHRadjBMI). Higher genetically determined BMI was associated with an increased risk of DLBCL [odds ratio (OR) per standard deviation (SD) = 1.18, 95% confidence interval (95% CI): 1.05-1.33, p = .005]. This finding was consistent with Mendelian randomization analyses, which demonstrated a similar increased risk of DLBCL with higher genetically determined BMI (OR_{per SD} = 1.12, 95% CI: 1.02-1.23, p = .03). No significant associations were observed with other NHL subtypes. Our study demonstrates a positive link between a genetically determined BMI and an increased risk of DLBCL, providing additional support for increased adiposity as a risk factor for DLBCL.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of immune checkpoint inhibitors on the pulmonary circulation in lung cancer patients.","authors":"Yao Xu, Qiuhong Zhang, Jie Gao, Shiyuan Yao, Chan Tian, Tuo He, Ming Zhang, Hu Shan, Jie Shi, Bo Yuan, Lei Wang, Xia Yang","doi":"10.1002/ijc.70110","DOIUrl":"https://doi.org/10.1002/ijc.70110","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) are effective anti-tumor agents, but new immune-related side effects (irAEs) are emerging. This retrospective cohort study investigated 461 lung cancer patients treated with ICIs over 2 years, analyzing changes in pulmonary artery diameter (PAD), aortic diameter (AoD), and the pulmonary artery/aortic diameter (PAD/AoD) ratio through chest computed tomography (CT) at baseline, 3 months, 6 months, 1 year, and 2 years post-treatment. The PAD increased from 25.19 to 26.33 mm (p < .001) and the PAD/AoD ratio increased from 0.70 to 0.73 (p < .001) during ICI treatment over a 2-year follow-up period, as early as within the first 3 months. High-sensitivity troponin I (hs-TnI), α-hydroxybutyrate dehydrogenase (HBDH), creatine kinase (CK), creatine kinase MB (CK-MB), and coagulation indices exhibited significant changes (p < .05), while the cardiac ultrasound result remained unchanged. In subgroup analysis, the severe group demonstrated lower overall survival (OS) (43 months vs. 56 months) (p = .008) and progression-free survival (PFS) (15 months vs. 20 months, p < .001) compared to the non-severe group. Meanwhile, the severe PAD/AoD ratio progression served as independent predictors of prognosis in lung cancer patients receiving ICI treatment, but immune-related pneumonia(CIP) did not significantly influence the PAD/AoD ratio progression (p > .999). Therefore, in lung cancer patients receiving ICIs, pulmonary vascular involvement can occur within the initial 3 months and needs to be monitored with chest CT and echocardiography.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145005613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Projected cancer burden attributable to population aging: Insight from a rapidly aging society.","authors":"Minh-Thao Tu, Hoejun Kwon, Yoon-Jung Choi, Hyunsoon Cho","doi":"10.1002/ijc.70125","DOIUrl":"https://doi.org/10.1002/ijc.70125","url":null,"abstract":"<p><p>Population aging is an increasing challenge for cancer control in rapidly aging societies, yet remains inadequately quantified. We aim to project and illustrate the cancer burden attributable to aging in Korea by utilizing age-period-cohort (APC) models and population attributable fraction (PAF) concepts. From population-based cancer data, incidence and mortality of cancers primarily affected by aging (stomach, colorectal, liver, gallbladder, pancreatic, lung, non-Hodgkin lymphoma, esophagus, prostate, ovarian, male bladder cancers, and female leukemia) and breast cancer were extracted. Aging-attributable fraction, cases, and deaths were estimated for older ages after projection to 2046 by APC models. Future cancer landscapes were projected to evolve due to population aging. While aging-related lung cancer may remain the highest (from 2017-2021: 94,990 cases, 71,726 deaths, PAF_mortality 78%; to 2042-2046: 220,251 cases, PAF_incidence 78%, 114,476 deaths, PAF_mortality 88%), the current high burden of stomach and liver cancers, likely related to infection, will shift to older age with reduced aging-attributable cases but increased PAF_incidence. Emerging burden will arise from lifestyle-related cancers, including colorectal cancer mortality (mortality-to-incidence ratio [MIR] of age ≥65 0.41 to 0.46) and prostate and breast cancer incidence (for age ≥65: 60,099 to 228,539 cases, PAF_incidence 74% to 86%; and 1316 to 31,874 cases, PAF_incidence 1% to 22%, respectively). Our findings highlight the coexistence of traditional and emerging burdens, which should be key priorities for cancer control programs when societies enter the upcoming super-aged decades. Efforts to mitigate forecasted trends are urgently required, including cancer prevention targeting middle-aged adults and cancer care for frail older patients.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Over one-third of cancer cases and two-fifths of cancer deaths in southern China are preventable: Insights from the latest representative population-based cancer registry data and risk factor survey.","authors":"Xiaolan Wen, Yu Liao, Jiayue Li, Qian Zhu, Xinmei Lin, Bingfeng Han, Li Li, Ru Chen, Ruilin Meng, Ni Xiao, Xueyan Zheng, Xiaojun Xu, Dejian Zhao, Yue Gao, Liming Pu, Ye Wang, Wenqiang Wei, Shaoming Wang","doi":"10.1002/ijc.70114","DOIUrl":"10.1002/ijc.70114","url":null,"abstract":"<p><p>Assessing the impact of modifiable risk factors on cancer is crucial for prioritizing effective prevention interventions. This study aimed to quantify the cancer burden attributable to modifiable risk factors in Guangdong in 2019, thereby informing targeted prevention strategies tailored to the region. The population attributable fraction (PAF) was estimated by Levin's method, based on the 2010 prevalence of 15 risk factors and the latest representative relative risks. PAFs for specific age groups, sexes, risk factors, and cancer types were then combined to obtain overall PAF. Attributable cancer cases were calculated using cancer burden data in 2019 and PAF estimate. 34.4% of incident cancer and 44.5% of cancer deaths in Guangdong were attributable to 15 potentially modifiable risk factors, with higher PAF among males (44.3% for incidence and 52.0% for mortality) than females (22.9% for incidence cancer and 29.9% for mortality). Ten of the twenty-two cancers exhibited an attributable fraction exceeding 50%, with five cancers exceeding 70%, including cancers of cervix uteri, nasopharynx, oral cavity and pharynx, liver and larynx. Behavioral factors contributed the most to incident cancer burden, followed by infectious, dietary, and metabolic factors. Nearly one-third of incident cancer and two-fifths of cancer deaths in Guangdong were preventable through addressing modifiable risk factors. The findings emphasize the critical need for targeted prevention strategies, particularly focusing on smoking, alcohol consumption, and infection control, to significantly reduce cancer burden. This study underscores the importance of integrating risk factor mitigation into public health policies to advance cancer prevention efforts in the region.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing viral footprints in circulating free DNA (cfDNA) for early cancer detection: A focus on liquid-biopsy-based screening.","authors":"Richard Donkor Amponsah, Emmanuel Addai Gyabaah, Moro Amidu, Zhao Cheng, Fazlur Rahman Talukdar","doi":"10.1002/ijc.70121","DOIUrl":"10.1002/ijc.70121","url":null,"abstract":"<p><p>Viral infections play a significant role in cancer development, making detecting viral signatures a promising approach for early cancer diagnosis. Circulating free DNA (cfDNA), released into the bloodstream by tumors and other cells, has emerged as a powerful biomarker for non-invasive cancer screening. This review explores the potential of cfDNA in detecting virus-associated cancers through the analysis of viral footprints. It provides a comprehensive overview of the biological mechanisms underlying cfDNA release, the role of oncogenic viruses in cancer progression, and the unique viral markers that can be traced within cfDNA. By leveraging viral genetic material, cfDNA analysis offers transformative potential for the early detection of virus-driven malignancies. Highlighting its clinical relevance, this review discusses how cfDNA-based viral biomarker screening could significantly enhance cancer monitoring, improve prognosis accuracy, and pave the way for innovative, non-invasive diagnostic tools and personalized cancer management strategies.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Her2 therapy patterns in metastatic breast cancer-Real-world data suggest undertreatment.","authors":"Kathrine F Vandraas, Sarah Hjorth, Cassia B Trewin-Nybråten, Giske Ursin, Edoardo Botteri, Bettina Kulle Andreassen, Kristin V Reinertsen, Egil S Blix, Bjørn Naume, Nathalie C Støer","doi":"10.1002/ijc.70120","DOIUrl":"https://doi.org/10.1002/ijc.70120","url":null,"abstract":"<p><p>Treatment efficacy of anti-HER2 therapies for metastatic breast cancer (mBC) has been demonstrated in clinical trials, but real-world data are lacking. In particular, it is unclear whether patients in clinical practice receive treatment as recommended. We took advantage of population-based registries in Norway to assess anti-HER2 therapy patterns in real-world data, with specific attention to the treatment of vulnerable groups. We included 715 patients with HER2+ mBC diagnosed from 2012 to 2021. Median age was 60 years, 473 (66%) had relapsed from early-stage BC, and 440 (62%) had hormone receptor positive (HR+) disease. Anti-HER2 therapy patterns aligned with national recommendations. Median treatment duration for first line therapy was 7.2 months, where 261 patients (55%) used trastuzumab and pertuzumab (±chemotherapy), followed by monotherapy with trastuzumab (195 patients, 41%). Second line therapy was initiated by 206 patients (43%), with a median duration of 7 months, where trastuzumab emtansine was the most prevalent therapy, used by 84 patients (41%). Third line therapy was initiated in 119 patients (25%) and 55 patients (11%) proceeded to fourth line therapy. The 182 patients (28%) who did not receive any anti-HER2 therapy were older (74 years vs. 55 years) and had more comorbidity compared to treated patients. Among patients ≤75 years and healthy, 15% did not receive anti-HER2 therapy. Patient characteristics strongly influence anti-HER2 treatment patterns, and although numerous treatment options are available, a substantial proportion of HER2+ mBC patients did not receive targeted therapy. Undertreatment may be present.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on \"Early-life anthropometry and colorectal cancer risk in adulthood: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis of prospective studies\".","authors":"Changyan Li","doi":"10.1002/ijc.70131","DOIUrl":"https://doi.org/10.1002/ijc.70131","url":null,"abstract":"","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Childhood acute leukemia and type 1 diabetes in children: A nationwide case-control study.","authors":"Julia Ventelä, Ida Pellikka, Anssi Auvinen, Olli Lohi, Atte Nikkilä","doi":"10.1002/ijc.70122","DOIUrl":"https://doi.org/10.1002/ijc.70122","url":null,"abstract":"<p><p>Etiology of childhood acute leukemia is largely unknown, though environmental factors and infection-related immune responses may contribute. Type 1 diabetes mellitus (T1DM), an autoimmune disease also with onset primarily in childhood, shares risk factors with leukemia, including childhood infection patterns. Epidemiological evidence suggests a link between T1DM and leukemia, but the extent of this association remains unclear. We identified 1626 leukemia cases diagnosed under 18 years of age (1990-2019) from the Finnish Cancer Registry, with three age- and sex-matched controls per case. Participants with Down syndrome or pancreatitis were excluded. Conditional logistic regression, adjusted for maternal smoking and large for gestational age, was used in the data analysis. Patients with T1DM, regardless of whether they were diagnosed before or after leukemia, demonstrated increased risk of acute leukemia, with an odds ratio (OR) of 2.0 (95% CI 1.1-3.5). The association was attenuated after adjustments (OR = 1.7, 95% CI 0.9-3.0). In the univariate analysis, a clear association was observed for acute lymphoblastic leukemia (ALL) (OR = 1.9, 95% CI 1.04-3.4) and an imprecise association of similar magnitude for acute myeloid leukemia (AML). For ALL diagnosed at ages 10-17 years, an OR of 5.4 (95% CI 1.8-16.1) was observed. The order of disease onset did not significantly impact the association. Our findings show an association between T1DM and acute leukemia, particularly ALL in older children, and treatment-related pancreatitis does not fully explain this co-occurrence. Further investigation is warranted to explore potential common etiological factors, such as infectious diseases.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}